Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a…

By M. Socinski, I. Bondarenko, N. Karaseva, A. Makhson, I. Vynnychenko, I. Okamoto, J. Hon, V. Hirsh, P. Bhar, Hui Zhang and 2 more. Journal of Clinical Oncology, 2012

663 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3ab3c7a7f709b7695f8f1d5e927054e0985adfb0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “• The nab-PC regimen has been shown in a large phase III trial to have a significantly higher ORR compared with solvent-based paclitaxel/carboplatin (sb-PC), and less neurotoxicity [I, B] [113].”
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “Some adverse events occurred at a lower rate with the intervention.(26) One trial used two recommended options; carboplatin plus docetaxel was the control arm, and pemetrexed plus carboplatin was the intervention arm.”
• Unraveling the mysteries of serum albumin—more than just a serum protein (2014, background): “Abraxane® has a greater therapeutic index than paclitaxel alone, being administered at higher doses with less toxicity and more efficacy than traditional paclitaxel therapy (Gradishar et al., 2005; Socinski et al., 2012; Iwamoto, 2013).”